January 4, 2012
Novogen Limited (NASDAQ:NVGND) opened the first trading session 2012 at $3.00 and set its new 52-high.
The trading tools registered the price change following the announcement that the company obtained a patent for treating cancer and tumors. The patent is expected to provide protection till September 2025.
The trading closed at $2.75 and the price change resulted in the decreasing trading volume of 2,463.00 which is almost ten times lower than its 30-day average. Over the recent year the company’s shares traded as low as $0.08. At the recently set price the company’s market capitalization stands at $8.19 million.
Novogen Limited is engaged in Biotechnology and Drugs industry of the Healthcare sector. The company is focused on pharmaceutical research and development, especially in the field of oncology.